Nuvalent (NUVL) Soars 16% After ALKOVE-1 Trial Shows 86% Response in TKI-Naïve Lung Cancer Patients
Nuvalent, Inc. (NASDAQ:NUVL) is a clinical-stage biotechnology company founded on the vision of designing precisely targeted therapies for…
Browsing Tag